I took profits

Do you have a number in mind?

My next number is, below 24, buy back in after the next negative news.

Not some musings from a chat board.

Good luck with your number.

JSATDS
(Just sitting at the desk smiling.)

Been Here quite a while.
The large postings of, mostly nonsense, just blot out the few posts I make.

I have taken the run over 27 to sell again, and will buy in as soon as the management team disapoints the market with a non news PR. Or another loss in court.

The investment community has made me a lot of money buying ansd selling IDCC.

I love this stock.

Just moved my money into ISIS, another stock that is slammed by over reaction.

take a look.

MeThinks the Daytraders are Here
The volume and price action look like there will be a sell-off at the close.


JMFO

The part about overselling, I got.

In fact I have been buying for a while. Unfortunately to get my basis down to a reasonable level.

Sadly it is a practice I have been using too often lately,

Am I Missing Something?

Stock up, with no new news.

PFE Just made an offer for a Drug Co.

I think with 200million shares outstanding this company is a cheap opportunity for $0.57 a share.

I see it breaking a buck soon.

They have Cash in the bank

That is some good news.

Any new NEWS expected at CC?

It would be good to hear something noteworthy, impactful to stock price, at the CC tomorrow.

I am afraid of same old same old.

I see it as an end of year report.
But it is still on indication of support.

as long as they didn't sell after the refinance.

It will be interesting to see the buying report for jan.

Notice; No One cares about investing in PHASE II

The investor community does not look at announcements of P II studies as worthwhile investment criteria. Sadly the failure of a P II study is only a reason to short or dump a stock.
They would be better off holding off announcements till the PII is underway.

Actually I looked at that as a reason to BUY

It was not a good reason for the drop as the recovery has shown. I was looking at the company itself. The Nokia decision never was factored into the guidance, since it seems to me the company only includes settled suits in future income projections.

I still am looking for a $30.00 stock without any good or bad news.

We are back to the Mid July level

Do we continue up to 30? Or is this too much too soon?

There was no reason to brop and I don't see a reason for the latest rise.

$9.00 is probably the bottom

The question remains how long will it stay in the $9.00 to $9.50 range?

There are other beat-up stocks that I coule buy and hope for a return to better levels also.

The Question is time value of money.

Who is the author?

Not New, but Serious

I was looking for the earnings release information.
This board is so busy with mindless chit chat that it is impossible to follow a thread.

Is there a way to review a thread?

News SOON?

Is there a schedule of release dates?

I really think the best play

is in CYTR. They own 36% of RXII and have their own PR out this morning that will kick them up today. Plus any good news on RXII will bereflected in CYTR.

JMO

Get ready to RUN

Very interesting news.
From the P.R.
CytRx President and CEO Steven A. Kriegsman, stated, “We believe bafetinib is a cutting-edge treatment that could be efficacious in a wide range of hematological cancers. Our objective is to evaluate results from this trial, and if successful, quickly progress into later-stage clinical trials either internally or with partners. An effective treatment could result in a multi-billion dollar oncology product for CytRx.”

http://finance.yahoo.com/news/CytRx-to-Conduct-Phase-2-bw-3616590555.html?x=0&.v=1

The news should get this stock up over $2.00 this week.

7 million shares traded by 1:00

Where the heck do all the shares come from without driving the price up?

Do we know any real Key Dates?

I see a lot of speculation but when is the next official date?

I think you sent a private massage to me about a misread news release causing the spike in cytr stock price.

Good Catch

But I wonder, will they turn and run?

Zix Finally defined themselves.

They are quitting the eRx business. the question will be what are the costs to get out of the contracts.

What article are you Guys jawing about?

Guidance that guides.

About time real news came out.

Should be a $4.00 stock real soon.

Your Point?

Xoma spends money on a lobbiest? I take as good news.

They have a pipeline of Unpartnered Product.

They have a history of partnered products.

The Xoma 052 has a lot of potential that a partner will come on board.

http://www.xoma.com/pipeline/overview/pipeline-chart/

You know they will be Higher soon

XOMA Will break out just like it has done in the past.

Buy now and feed the rush later.

Remember "BUY LOW, SELL HIGH"

Xoma is your big chance to get it right.....

This sleeping beauty will wake with a kiss from Prince Charming.

I expect a 4 bagger by year end.

Shorts must cover if

the brokerage does not have shares to lend the short.

Legally the brokerage must have shares in someones account to lend to the short seller. If the long decides to sell his stock the short must cover.

It happened to me with Scottrade on a thin stock I shorted once.

Caused a squeeze for me.

Somebody Likes them

Interesting Recommendation


Rodman & Renshaw initiates RXII with a Mkt Outperform and price target of $8. The firm considers RNA interference to be among the most significant recent discoveries in biology, and they believe that its translation into medicines could provide answers for multiple therapeutic areas, given the technology's potential to address diseases that are considered "undruggable" by currently available therapeutic modalities. The firm views RXII as being among a very small number of second-generation or "follow-on" young companies in the space, since it possesses the unique combination of singular focus on RNAi, top notch scientific advisors, and expertise in the development of RNA-based therapeutics. The firm believes that this combination of characteristics, make RXII part of a handful of companies with the potential to follow on a path similar to Alnylam in its early days, and a company that could eventually become one of the few early winners in the space of RNA-based therapeutics.


CYTR owns 36% of this company.

Guess Who Owns 36%

RXII $3.00 stock

Rodman & Renshaw initiates RXII with a Mkt Outperform and price target of $8. The firm considers RNA interference to be among the most significant recent discoveries in biology, and they believe that its translation into medicines could provide answers for multiple therapeutic areas, given the technology's potential to address diseases that are considered "undruggable" by currently available therapeutic modalities. The firm views RXII as being among a very small number of second-generation or "follow-on" young companies in the space, since it possesses the unique combination of singular focus on RNAi, top notch scientific advisors, and expertise in the development of RNA-based therapeutics. The firm believes that this combination of characteristics, make RXII part of a handful of companies with the potential to follow on a path similar to Alnylam in its early days, and a company that could eventually become one of the few early winners in the space of RNA-based therapeutics.

It's beginning to look like Dead Money.

At least until next year.

$25 is looking to me to be a stop in both directions.

I wanted to pay some christmas bills with IDCC at 28.

3AB is not even Phase I.

XOMA 052 is currently in Phase 1 clinical studies in Type 2 diabetes patients but what kind of money is going to come from it?

And when?

What does the news mean to me?

Assessments?

Nice if you are right.....

Unloved by Motley Fool

XOMA (Nasdaq: XOMA): $0.71
Biotech investing can be more art than science when we're talking about the XOMA gamble. Sure, the specialist in antibody therapeutics has been trading publicly since the 1980s, but a few swings and misses find the biotech survivor back on the farm team of the stock market.

XOMA 052 isn't a jersey number. It's the company's best shot at a potential blockbuster on the diabetes front. The catch is that the compound has completed just the first phase of clinical trials. Even if things go well for the treatment, it may not hit the market for years

I think we will continue to see this steady uptrend

till year end.
Unless there is bad or perceived bad news.
Good news will not make much of a difference in the trend.

But profit taking at year end should not surprise anyone.

I for one have booked enough losses to make any profit a free ride.

Looks like They are Unloved.

Might be a good time to unload and buy a different penny stock.

Only this time I will start with a stock below a dollar.

Any suggestions?

Buyers are conflicted

RXII and cytr seem to be confusing potential buyers.

I cannot figure out why anyone is buying rxii when cytr ownes 36% so any upside is passed on to cytr.

But someone probably knows something we don't.